Influence of HRT on prognostic factors for breast cancer: A systematic review after the Women's Health Initiative trial

Human Reproduction

Volumn 19, Issue 3, 2004, Pages 741-756

  Antoine, Caroline ^a   Liebens, Fabienne ^a   Carly, Birgit ^a   Pastijn, Anne ^a   Rozenberg, Serge ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Breast cancer; HRT; Prognosis; Systematic review

Indexed keywords

CATHEPSIN D; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; PLACEBO; PROTEIN BCL 2; PROTEIN P53; S PHASE KINASE ASSOCIATED PROTEIN; STEROID RECEPTOR; UVOMORULIN;

ADULT; ADVANCED CANCER; AGED; BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RISK; CANCER SURGERY; CARCINOMA IN SITU; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; MEDICAL LITERATURE; MEDULLARY CARCINOMA; MENOPAUSAL SYNDROME; METHODOLOGY; PAGET NIPPLE DISEASE; PAPILLARY CARCINOMA; PATIENT SELECTION; PROGNOSIS; REVIEW; SAMPLE SIZE; STATISTICAL DISTRIBUTION;

EID: 1542711550     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/deh112     Document Type: Review

References (53)

1. Aerts M, Neven P, Drijkoningen R, Morales L, Paridaens R, Berteloot P, Amant F, Christiaens M-R and Vergote IB (2003) Are breast cancers in patients on hormone replacement therapy different from the classical breast cancer? In Abstracts of the 13th International Meeting of The European Society of Gynaecological Oncology (ESGO), Brussels, Belgium, April 6-10, 2003. Int J Gyn Cancer 13(Suppl 1),1-122.
2. Beral V and the Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362,419-427.
3. Bergkvist L, Adami HO, Persson I, Bergstrom R and Krusemo UB (1989) Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 130,221-228.
4. Bilimoria MM, Winchester DJ, Sener SF, Motykie G, Sehgal UL and Winchester DP (1999) Estrogen replacement therapy and breast cancer: analysis of age of onset and tumor characteristics. Ann Surg Oncol 6,200-207.
5. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM and Piana L (1995) Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 85,11-17.
6. Bonnier P, Bessenay F, Sasco AJ, Beedassy B, Lejeune C, Romain S, Charpin C, Piana L and Martin PM (1998) Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer. Int J Cancer 79,278-282.
7. Bonnier P, Sakr R, Bessenay F, Lejeune C, Charpin C, Martin PM and Piana L (2000) Effects of hormone replacement therapy for menopause on prognostic factors of breast cancer. Gynecol Obstet Fertil 28,745-753.
8. Cheek J, Lacy J, Toth-Fejel S, Morris K, Calhoun K and Pommier RF (2002) The impact of hormone replacement therapy on the detection and stage of breast cancer. Arch Surg 137,1015-1019; discussion 1019-1021.
9. Chen CL, Weiss NS, Newcomb P, Barlow W and White E (2002) Hormone replacement therapy in relation to breast cancer. JAMA 287,734-741.
10. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA et al. (2003) WHI Investigators. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. JAMA 289,3243-3253.
11. Cobleigh MA, Norlock FE, Oleske DM and Starr A (1999) Hormone replacement therapy and high S phase in breast cancer. JAMA 281,1528-1530.
12. Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350,1047-1059.
13. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G et al. (2002) Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer 95,2455-2464.
14. Delgado RC and Lubian Lopez DM (2001) Prognosis of breast cancers detected in women receiving hormone replacement therapy. Maturitas 38,147-156.
15. Diel IJ, Schuetz F, Puschel M, Solomayer EF, Von Holst T, Haus U, Kohnen R and Bastert G (2002) Reduced incidence of metastases in breast cancer patients treated with preoperative hormone replacement therapy (HRT): A retrospective study in 1160 women. The 25th Annual Symposium of San Antonio, December, 2002. Abstract. Available online at: http://sabcs.org/SymposiumOnline/index.aspabstracts
16. Estève J, Seradour B, Jacquemier J and Remontet L (2002) Does a better grade of tumour occurring in women under hormone replacement therapy compensate for their lower probability of detection by screening mammography. J Med Screen 9,70-73.
17. Faiz O and Fentiman IS (1998) Hormone replacement therapy and breast cancer. Int J Clin Pract 52,98-101.
18. Fowble B, Hanlon A, Freedman G, Patchefsky A, Kessler H, Nicolaou N, Hoffman J, Sigurdson E, Boraas M and Goldstein L (1999) Postmenopausal hormone replacement therapy: Effect on diagnosis and outcome in early-stage invasive breast cancer treated with conservative surgery and radiation. J Clin Oncol 17,1680-1688.
19. Gajdos C, Tartter PI and Babinszki A (2000) Breast cancer diagnosed during hormone replacement therapy. Obstet Gynecol 95,513-518.
20. Gapstur SM, Morrow M and Sellers TA (1999) Hormone replacement therapy and risk of breast cancer with a favorable histology: results of the Iowa Women's Health Study. JAMA 281,2091-2097.
21. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ et al. (1997) Postmenopausal hormone therapy and mortality. N Engl J Med 336,1769-1775.
22. Grodstein F, Clarkson TB and Manson JE (2003) Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 348,645-650.
23. Harding C, Knox WF, Faragher EB, Baildam A and Bundred NJ (1996) Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. BMJ 312,1646-1647.
24. Henrich JB, Kornguth PJ, Viscoli CM and Horwitz RI (1998) Postmenopausal estrogen use and invasive versus in situ breast cancer risk. J Clin Epidemiol 51,1277-1283.
25. Holli K, Isola J and Cuzick J (1997) Hormone replacement therapy and biological aggressiveness of breast cancer. Lancet 350,1704-1705.
26. Holli K, Isola J and Cuzick J (1998) Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. J Clin Oncol 16,3115-3120.
27. Huang E, Cheng SH, Dressman H, Pittman J, Tsou MH, Horng CF, Bild A, Iversen ES, Liao M and Chen CM et al. (2003) Gene expression predictors of breast cancer outcomes. Lancet 361,1590-1596.
28. Jernström H, Frenander J, Ferno M and Olsson H (1999) Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 80,1453-1458.
29. Jones C, Ingram D, Mattes E and Hahnel R (1994) The effect of hormone replacement therapy on prognostic indices in women with breast cancer. Med J Aust 161,106-110.
30. Kavanagh AM, Mitchell H and Giles GG (2000) Hormone replacement therapy and accuracy of mammographic screening. Lancet 355,270-274.
31. Klein P, Gallinson D, Siegel B, Vallejo C, Kornrich D and Axelrod D (2003) Postmenopausal females who develop breast cancer after using hormone replacement therapy (HRT) have an increased incidence of invasive lobular carcinoma. The ASCO Annual Meeting, May 31 to June 3, 2003 Chicago, IL. Abstract 3583. Available online at: http://www.asco.org/ac/1,1003,_12-002138,00.asp
32. Laya MB, Larson EB, Taplin SH and White E (1996) Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography. J Natl Cancer Inst 88,643-649.
33. LeBlanc ES, Viscoli CM and Henrich JB (1999) Postmenopausal estrogen replacement therapy is associated with adverse breast cancer prognostic indices. J Womens Health Gend Based Med 8,815-823.
34. Li CI, Weiss NS, Stanford JL and Daling JR (2000) Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88,2570-2577.
35. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, Cushing-Haugen KL and Daling JR (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA 289,3254-3263.
36. Lower EE, Blau R, Gazder P and Stahl DL (1999) The effect of estrogen usage on the subsequent hormone receptor status of primary breast cancer. Breast Cancer Res Treat 5 8,205-211.
37. Magnusson C, Holmberg L, Norden T, Lindgren A and Persson I (1996) Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 38,325-334.
38. Manjer J, Malina J, Berglund G, Bondeson L, Garne JP and Janzon L (2001) Increased incidence of small and well-differentiated breast tumours in postmenopausal women following hormone-replacement therapy. Int J Cancer 92,919-922.
39. Nanda K, Bastian LA and Schulz K (2002) Hormone replacement therapy and the risk of death from breast cancer: A systematic review. Am J Obstet Gynecol 186,325-334.
40. Newcomer LM, Newcomb PA, Potter JD, Yasui Y, Trentham-Dietz A, Storer BE, Longnecker MP, Baron JA and Daling JR (2003) Postmenopausal hormone therapy and risk of breast cancer by histologic type (United States). Cancer Causes Control 14, 225-233.
41. O'Connor IF, Shembekar MV and Shousha S (1998) Breast carcinoma developing in patients on hormone replacement therapy: A histological and immunohistological study. J Clin Pathol 51,935-938.
42. Persson I, Yuen J, Bergkvist L and Schairer C (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy - long-term follow-up of a Swedish cohort. Int J Cancer 67,327-332.
43. Ross RK, Paganini-Hill A, Wan PC and Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. J Natl Cancer Inst 92,328-332.
44. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 288,321-333.
45. Sacchini V, Zurrida S, Andreoni G, Luini A, Galimberti V, Veronesi P, Intra M, Viale G and Veronesi U (2002) Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. Ann Surg Oncol 9,266-271.
46. Salmon RJ, Remvikos Y, Ansquer Y and Asselain B (1995) HRT and breast cancer. Lancet 346,1702-1703.
47. Salmon RJ, Ansquer Y, Asselain B, Languille O, Lesec G and Remvikos Y (1999) Clinical and biological characteristics of breast cancers in postmenopausal women receiving hormone replacement therapy for menopause. Oncol Rep 6,699-703.
48. Schairer C, Gail M, Byrne C, Rosenberg PS, Sturgeon SR, Brinton LA and Hoover RN (1999) Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 91,264-270.
49. Squitieri R, Tartter PI, Ahmed S, Brower ST and Theise ND (1994) Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 178,167-170.
50. Stallard S, Litherland JC, Cordiner CM, Dobson HM, George WD, Mallon EA and Hole D (2000) Effect of hormone replacement therapy on the pathological stage of breast cancer: Population based, cross sectional study. BMJ 320,348-349.
51. Stolier AJ, Mera R and Schapira D (1998) The impact of current use of hormone replacement therapy on prognostic factors and surgical treatment of new breast cancers. Oncol Rep 5,61-464.
52. vande Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347,1999-2009.
53. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, Norman SA, Bernstein L, Ursin G, Marchbanks PA et al. (2002) Hormone replacement therapy regimens and breast cancer risk (1). Obstet Gynecol 100,1148-1158.